Egle Therapeutics to Present Preclinical Data on EGL-001 at Immunotherapy of Cancer Meeting

PARIS, France I October 25, 2024 I Egle Therapeutics, a company specializing in the advancement of regulatory T cell-focused treatments for cancer and autoimmune disorders, is set to present its latest research at the Society for Immunotherapy of Cancer (SITC) Meeting in Houston, Texas from November 6th to 10th, 2024.

The upcoming presentation, titled “Preferential tumor retention of EGL-001, a CTLA-4/CD25 antagonist fusion protein, to selectively deplete tumor Tregs and minimize peripheral toxicities: towards a first-in-human clinical study”, will focus on the development and encouraging preclinical outcomes of EGL-001. This humanized antibody aims to selectively eliminate regulatory T cells (Tregs) within the tumor microenvironment. The findings point to EGL-001’s potential to act independently and to bolster the efficacy of immune checkpoint blockade therapies by targeting tumor-associated Tregs. This targeting leads to enhanced activation of CD8+ T cells and stronger anti-tumor responses in preclinical models.

The presentation at SITC will reveal significant results from research conducted on mouse models and cynomolgus monkeys. These studies demonstrate the safety, tolerability, and effectiveness of EGL-001, along with its ability to accumulate preferentially in tumors while being swiftly cleared from peripheral tissues. These positive preclinical findings are paving the way for Egle Therapeutics to initiate a first-in-human, open-label, phase I/II clinical trial. This trial is designed to assess the safety, tolerability, pharmacokinetics, and preliminary activity of EGL-001 in patients with specific solid tumors, addressing the critical demand for more effective cancer immunotherapies.

The session is scheduled for Saturday, Nov. 9 at the George R. Brown Convention Center, Level 1, Exhibit Halls AB, with the poster board number 674.

Egle Therapeutics SAS (Egle) is a clinical-stage biotechnology firm dedicated to the development of immunotherapies aimed at suppressive regulatory T cells. Utilizing a proprietary discovery platform, Egle seeks to uncover novel Treg-specific targets and create innovative Treg-focused treatments for cancer and autoimmune diseases. Currently, Egle's most advanced oncology drug candidate, EGL-001 (a Treg-selective anti-CTLA4-IL-2m), is undergoing a Phase I/II clinical trial. In the field of autoimmunity, the company is working on advancing EGL-003 (non-targeted IL-2 Treg engager), which is currently in IND-enabling studies.
 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!